Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

O Bloqueio do Plano Intercostal Parasternal Profundo Reduz o Consumo de Opioides Após Esternotomia

10 de novembro de 2026 atualizado por: Burak Cemil Balık, Gaziantep City Hospital

Preoperative Ultrasound-Guided Deep Parasternal Intercostal Plane Block and Intraoperative Opioid Consumption in Adults Undergoing Cardiac Surgery Via Median Sternotomy

Median sternotomy is commonly used in cardiac surgery and is associated with significant intraoperative and postoperative pain, often requiring substantial opioid administration. High opioid use during cardiac surgery may contribute to adverse effects such as respiratory depression, delayed extubation, postoperative nausea and vomiting, and prolonged intensive care unit stay. Therefore, effective opioid-sparing strategies are an important component of modern perioperative care.

The deep parasternal intercostal plane (DPIP) block is a regional anesthesia technique that targets the anterior cutaneous branches of the intercostal nerves, which are responsible for transmitting pain from the sternum and adjacent tissues. When performed under ultrasound guidance, this block allows precise local anesthetic deposition while minimizing the risk of pleural or vascular injury.

The purpose of this randomized controlled study is to evaluate whether a preoperative ultrasound-guided DPIP block reduces intraoperative opioid consumption in adult patients undergoing elective cardiac surgery via median sternotomy. Patients will be randomly assigned to receive either a bilateral DPIP block in addition to standard general anesthesia or standard general anesthesia alone.

The primary outcome of the study is total intraoperative opioid consumption. Secondary outcomes include time to extubation, postoperative opioid consumption within the first 24 hours, postoperative pain scores, and the incidence of opioid-related adverse effects. The results of this study may help define the role of the DPIP block as part of a multimodal, opioid-sparing analgesic strategy in cardiac surgery.

Visão geral do estudo

Descrição detalhada

Adequate pain control during and after cardiac surgery via median sternotomy remains challenging despite advances in perioperative care. Opioids continue to be the mainstay of analgesia; however, excessive intraoperative opioid administration has been associated with delayed extubation, respiratory complications, postoperative nausea and vomiting, and prolonged intensive care unit stay. As part of enhanced recovery protocols, regional anesthesia techniques that provide effective opioid-sparing analgesia are increasingly emphasized.

The deep parasternal intercostal plane (DPIP) block is a relatively novel ultrasound-guided regional anesthesia technique that targets the anterior cutaneous branches of the intercostal nerves within the fascial plane between the internal intercostal and transversus thoracis muscles. Compared with more proximal neuraxial or paravertebral techniques, the DPIP block offers a more localized and anatomically specific approach to sternotomy-related pain while potentially reducing the risk of serious complications.

In this prospective, randomized controlled trial, adult patients scheduled for elective cardiac surgery via median sternotomy will be allocated to one of two parallel groups. Patients in the intervention group will receive a bilateral ultrasound-guided DPIP block performed preoperatively after induction of general anesthesia, in addition to standardized general anesthesia management. Patients in the control group will receive standardized general anesthesia alone, without a regional block. Perioperative anesthetic management, including opioid administration, will follow institutional protocols and will be guided by routine clinical parameters.

The primary objective of the study is to assess the effect of the preoperative DPIP block on total intraoperative opioid consumption. Secondary objectives include evaluation of early recovery parameters such as time to extubation, postoperative opioid requirements within the first 24 hours, postoperative pain intensity, and the occurrence of opioid-related adverse events. Safety outcomes related to the block procedure will also be recorded.

This study is designed to provide clinically relevant data on the role of the DPIP block as part of a multimodal analgesic strategy in cardiac surgery. By focusing on intraoperative opioid consumption and early recovery outcomes, the trial aims to clarify whether preoperative application of this targeted regional technique can contribute to improved perioperative management and opioid-sparing anesthesia in patients undergoing median sternotomy.

Tipo de estudo

Intervencional

Inscrição (Real)

81

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Sahinbey
      • Gaziantep, Sahinbey, Turquia (Türkiye)
        • Gaziantep Sehir Hastanesi

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Adults aged 18 to 65 years Scheduled to undergo elective cardiac surgery via median sternotomy Planned general anesthesia Able to provide written informed consent Sufficient cognitive capacity to participate in postoperative clinical assessments.

Exclusion Criteria:

Emergency cardiac surgery. Cardiac surgery performed through an approach other than median sternotomy. Redo sternotomy. Known allergy or hypersensitivity to amide local anesthetics. Clinically significant coagulopathy or antithrombotic treatment contraindicating regional anesthesia according to the institutional protocol.

Infection or impaired skin integrity at or near the planned block site. Unstable clinical conditions considered to increase the risk of pleural complications.

Chronic opioid use. Pre-existing chronic pain syndromes. Major musculoskeletal deformity affecting pain assessment. Neurological or psychiatric disorders preventing valid postoperative assessment.

Clinically significant peripheral neuropathy. Severe pulmonary disease. Pregnancy or lactation. Severe cognitive impairment or inability to communicate pain intensity. Refusal or inability to provide written informed consent. Inability to comply with the study protocol.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Deep Parasternal Intercostal Plane Block Group

Participants receive bilateral ultrasound-guided deep parasternal intercostal plane (DPIP) block after induction of general anesthesia and before median sternotomy, in addition to standardized general anesthesia and protocolized intraoperative opioid management. Remifentanil is titrated according to predefined clinical and hemodynamic criteria, with rescue fentanyl administered when indicated.

Bilateral ultrasound-guided deep parasternal intercostal plane block is performed after induction of general anesthesia and before median sternotomy. Bupivacaine 0.25% is injected into the fascial plane between the internal intercostal and transversus thoracis muscles, using 10 mL (25 mg) per side, for a total volume of 20 mL and a total dose of 50 mg.

Standardized general anesthesia is administered according to the institutional cardiac anesthesia protocol. Intraoperative remifentanil infusion is initiated at 0.05 µg/kg/min and titrated according to predefined clinical and hemodynamic criteria, with a maximum infusion rate of 0.2 µg/kg/min. Rescue fentanyl (0.5 µg/kg intravenously) is administered when clinically indicated according to the protocol. The same opioid titration criteria are applied in both study groups; actual opioid doses vary according to individual patient requirements.

Comparador Ativo: Standard Analgesia (Control) Group

Participants receive standardized general anesthesia and the same protocolized intraoperative opioid management as the DPIP group, without any regional anesthesia technique. Remifentanil is titrated according to the same predefined clinical and hemodynamic criteria, with rescue fentanyl administered when indicated.

Standardized general anesthesia is administered according to the institutional cardiac anesthesia protocol. Intraoperative remifentanil infusion is initiated at 0.05 µg/kg/min and titrated according to predefined clinical and hemodynamic criteria, with a maximum infusion rate of 0.2 µg/kg/min. Rescue fentanyl (0.5 µg/kg intravenously) is administered when clinically indicated according to the protocol. The same opioid titration criteria are applied in both study groups; actual opioid doses vary according to individual patient requirements.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Total Intraoperative Opioid Consumption
Prazo: From induction of general anesthesia until completion of surgery

Total intraoperative opioid consumption recorded from anesthesia records. In the remifentanil-based protocol, opioid consumption will be assessed primarily as total remifentanil dose, duration-normalized remifentanil consumption, and weight- and duration-normalized remifentanil consumption. Rescue fentanyl use will be recorded separately.

From induction of general anesthesia until completion of surgery

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Intraoperative Hemodynamic Stability
Prazo: During surgery

Incidence of intraoperative hemodynamic instability, defined as the need for additional opioid administration or vasoactive support in response to surgical stimulation, recorded from anesthesia records.

During surgery
Time to Extubation
Prazo: From completion of surgery to successful tracheal extubation in the intensive care unit

Time elapsed between the end of surgery and successful tracheal extubation, recorded in minutes.

From completion of surgery to successful tracheal extubation in the intensive care unit
Postoperative Opioid Consumption
Prazo: First 24 hours postoperatively

Cumulative amount of opioids administered during the first 24 postoperative hours, expressed as intravenous morphine equivalents (mg), obtained from medical records.

First 24 hours postoperatively
Time to First Rescue Analgesia
Prazo: Up to 24 hours postoperatively

Time elapsed from arrival in the intensive care unit to the administration of the first rescue analgesic medication.

Up to 24 hours postoperatively
Block-Related Complications
Prazo: Intraoperative period and first 24 postoperative hours

Incidence of complications related to the parasternal intercostal plane block, including but not limited to pneumothorax, vascular puncture, local anesthetic systemic toxicity, and infection.

Intraoperative period and first 24 postoperative hours

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

12 de fevereiro de 2026

Conclusão Primária (Real)

7 de junho de 2026

Conclusão do estudo (Real)

8 de junho de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

18 de dezembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

18 de dezembro de 2025

Primeira postagem (Real)

2 de janeiro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data will not be shared, as the study is a single-center clinical trial and data sharing was not included in the original study protocol or approved by the institutional ethics committee. De-identified aggregate data will be reported in scientific publications.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever